TOKYO -- VLP Therapeutics Japan has begun a clinical trial of a new coronavirus vaccine that would require a far smaller dosage than those of Pfizer and Moderna, and could dramatically shorten production time, the company said Monday.
The company, a subsidiary of a U.S. drug startup founded by Japanese researchers, has developed the vaccine in partnership with six Japanese research institutes, including Oita University, Hokkaido University and the National Center for Global Health and Medicine.
